Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 13/20 | 0.52 |
| ▸ | OGA | O60502 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3606423 | 0.85 | P2RY12 (0.59) | P2RY12OGAHRH3SGPL1KMT2A | |
| SCHEMBL13491145 | 0.82 | SMO (0.63) | P2RY12HRH3SGPL1SMO | |
| SCHEMBL13491029 | 0.82 | SMO (0.47) | HRH3SMO | |
| SCHEMBL13491143 | 0.82 | SMO (0.62) | P2RY12HRH3SGPL1SMO | |
| SCHEMBL13491027 | 0.79 | SMO (0.44) | OGAKMT2AMEN1SMO | |
| SCHEMBL2820792 | 0.79 | P2RY12 (0.64) | P2RY12OGAHRH3KMT2AMEN1 | |
| SCHEMBL7469230 | 0.78 | P2RY12 (0.63) | P2RY12OGAHRH3KMT2AMEN1 | |
| SCHEMBL13491028 | 0.77 | SMO (0.47) | OGAKMT2AMEN1SMO | |
| SCHEMBL9210857 | 0.77 | P2RY12 (0.65) | P2RY12OGAHRH3SGPL1KMT2A | |
| SCHEMBL7529775 | 0.76 | P2RY12 (0.64) | P2RY12OGAHRH3SGPL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409871-B2 | Pyridazinyl derivatives as SMO inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-8481542-B2 | Pyridazinyl derivatives as smo inhibitors | NOVARTIS AG (CH) | 2013-07-09 | — | — | US | disclosed |
| EP-2318389-B1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-20120289507-A1 | ORGANIC COMPOUNDS AS SMO INHIBITORS | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
| EP-2318389-A1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | Novartis AG (CH) | 2011-05-11 | — | — | EP | disclosed |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| WO-2010007120-A1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | SMO, SHH, GLI1 | P2RY12 1290/4885OGA 3903/4885HRH3 373/4885 |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | SMO, GLI1, SHH | P2RY12 4432/4885OGA 360/4885HRH3 1719/4885 |
| US-20120289507-A1 | ORGANIC COMPOUNDS AS SMO INHIBITORS | SMO, GLI1, SHH | P2RY12 4432/4885OGA 360/4885HRH3 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.